Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases.

Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy. That being said, the B6 sensitivity was difficult to assess in Patients 1 and 3 since PH1 was diagnosed at the time of kidney failure, and in Patient 5, despite maximal B6 therapy at the time of conservative therapy, an important hyperoxaluria remained. Among patients who reach kidney failure, intensive hemodialysis should be performed; however, systemic oxalosis worsens despite intensive dialysis, and bone is the main compartment for oxalate storage. However, the proposed thresholds of POx for a safe transplant procedure, namely around 20 µmol/L [[13]], appear quite optimistic and probably not attainable in most patients, keeping in mind the POx levels observed in dialysis in non-PH1 patients. [Extracted from the article]